Arno Therapeutics to Present at Biotech Showcase 2014
January 09 2014 - 8:30AM
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage
biopharmaceutical company focused on the development of oncology
therapeutics, today announced that Chief Executive Officer Glenn
Mattes is scheduled to present at Biotech Showcase™ 2014, taking
place January 13-15, 2014 in San Francisco, Calif.
Mr. Mattes will present on Wednesday, January 15, 2014 at 10:00
a.m. PST to attending investors, pharmaceutical and healthcare
executives. During his presentation, Mr. Mattes will discuss Arno's
business and growth strategy, clinical developments of its lead
oncology candidate, onapristone, and accompanying companion
diagnostic. Mr. Mattes will also discuss recent milestones,
including the start of Arno's Phase I clinical trial for
onapristone in progesterone receptor positive tumors.
Details of the presentation are as follows:
Date: |
Wednesday, January 15, 2014 |
Time: |
10:00 a.m. PST |
Place: |
Parc 55 Wyndham San Francisco, Union
Square |
Track: |
C - Mission II (3rd Floor) |
Investors and analysts interested in scheduling a 1-on-1 meeting
with the Arno management team during the conference may do so by
contacting Lee Roth of The Ruth Group at
lroth@theruthgroup.com.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company
developing innovative products for the treatment of cancer. Arno
has exclusive worldwide rights to develop and market three
innovative anti-cancer product candidates. These compounds are in
clinical or preclinical development as product candidates to treat
hematologic malignancies and solid tumors. For more information
about the company, please visit www.arnothera.com.
About Biotech Showcase™ 2014
Biotech Showcase™ is an investor and partnering conference
devoted to providing private and small- and mid-cap biotechnology
companies an opportunity to present to and meet with investors and
biopharmaceutical executives during the course of one of the
largest annual healthcare conferences that attracts investors and
biopharmaceutical executives from around the world.
The 2013 edition showed a substantial increase in the number of
presenting companies, as well as significant growth in the number
of attendees and one-to-one meetings. The 2013 event featured
corporate presentations by 236 public and private biotechnology and
life science companies, and drew 1,600 delegates who engaged in
2,500 one-to-one meetings.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. These statements are
often, but not always, made through the use of words or phrases
such as "anticipates," "expects," "plans," "believes," "intends,"
and similar words or phrases. These forward-looking statements
include, without limitation, statements regarding the timing,
progress and anticipated results of the clinical development of
onapristone and accompanying companion diagnostic, as well as
Arno's strategy, future operations, outlook, milestones, future
financial position, future financial results, plans and objectives.
We may not actually achieve these plans, intentions or expectations
and Arno cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that we make. Such factors include,
among others, risks that the results of clinical trials will not
support our claims or beliefs concerning the effectiveness of
onapristone or any of our other product candidates, our ability to
finance the development of our product candidates, regulatory
risks, and our reliance on third party researchers and other
collaborators. Additional risks are described in the company's
Annual Report on Form 10-K for the year ended December 31, 2012.
Arno is providing this information as of the date of this press
release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future
events or otherwise.
CONTACT: The Ruth Group
Lee Roth (investors)
lroth@theruthgroup.com
(646) 536-7012
Kirsten Thomas (media)
kthomas@theruthgroup.com
(646) 536-7014
Arno Therapeutics
Glenn Mattes
gm@arnothera.com
(862) 703-7176
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024